학술논문

Germline SAMD9 and SAMD9L mutations are associated with extensive genetic evolution and diverse hematologic outcomes
Document Type
article
Source
JCI Insight. 3(14)
Subject
Pediatric Cancer
Hematology
Genetics
Cancer
Childhood Leukemia
Rare Diseases
Clinical Research
Pediatric
2.1 Biological and endogenous factors
Aetiology
Cell Cycle
Chromosome Deletion
Chromosome Disorders
Chromosomes
Human
Pair 7
Disease Progression
Evolution
Molecular
Female
Gene Expression Regulation
Neoplastic
Genetic Predisposition to Disease
Germ-Line Mutation
Hematologic Neoplasms
Humans
Intracellular Signaling Peptides and Proteins
Leukemia
Myeloid
Acute
Male
Myelodysplastic Syndromes
Neoplasms
Pedigree
Proteins
Tumor Suppressor Proteins
Leukemias
Language
Abstract
Germline SAMD9 and SAMD9L mutations cause a spectrum of multisystem disorders that carry a markedly increased risk of developing myeloid malignancies with somatic monosomy 7. Here, we describe 16 siblings, the majority of which were phenotypically normal, from 5 families diagnosed with myelodysplasia and leukemia syndrome with monosomy 7 (MLSM7; OMIM 252270) who primarily had onset of hematologic abnormalities during the first decade of life. Molecular analyses uncovered germline SAMD9L (n = 4) or SAMD9 (n = 1) mutations in these families. Affected individuals had a highly variable clinical course that ranged from mild and transient dyspoietic changes in the bone marrow to a rapid progression of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) with monosomy 7. Expression of these gain-of-function SAMD9 and SAMD9L mutations reduces cell cycle progression, and deep sequencing demonstrated selective pressure favoring the outgrowth of clones that have either lost the mutant allele or acquired revertant mutations. The myeloid malignancies of affected siblings acquired cooperating mutations in genes that are also altered in sporadic cases of AML characterized by monosomy 7. These data have implications for understanding how SAMD9 and SAMD9L mutations contribute to myeloid transformation and for recognizing, counseling, and treating affected families.